Dr. Yan Liu recently joined EORTC Headquarters as a fellow in the Translational Research, Radiotherapy and Imaging Department

Dr. Yan Liu completed her medical studies at the Shanghai Jiaotong University College of Medicine in Shanghai, China, where she also received her Master of Medicine in Image Diagnosis. Following her medical studies she spent two years as a resident radiologist in the imaging diagnosis center at the Shanghai Children’s Medical Center.

In September 2007 Yan was awarded a scholarship to study neonatal brain structure by diffusion tensor imaging and tractography in the Neuroradiology Department at the Erasmus Hospital in Brussels, where she also served as a visiting physician. Yan reports that she had the opportunity to become familiar with brain tumors at Erasmus Hospital as “we worked with a neuro-oncology team which involved neuro-surgeons, oncologists, radiologists, pathologists, physicians for PET, and psychologists”.

She will defend her Ph.D. thesis, “In-vivo evaluation of brain structure in preterm neonates at term-equivalent time: Contribution of diffusion tensor imaging and probabilistic tractography”, in January 2012.

At EORTC Headquarters, Dr. Liu will be involved in a wide range of imaging activities. Initially these will involve her participation in the QuIC-ConCePT and Euro‐BioImaging projects. QuIC-ConCePT (Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy), through a grant provided by the Innovative Medicines Initiative, aims to qualify imaging biomarkers of tumor cell proliferation, apoptosis, and necrosis that will allow drug developers to reliably demonstrate the modulation of these pathologic processes in tumors in patients in cancer clinical trials. Euro‐BioImaging is a pan‐European research infrastructure project focusing on biological and biomedical imaging.

We at the EORTC Headquarters are pleased to have Yan on board.

John Bean

Back to news list

Related News

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation

  • Long-term follow-up of chemoradiotherapy treatment in glioma patients shows significantly increased survival

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older patients with acute myeloid leukemia

  • Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

  • EORTC and Alliance Healthcare’s continued partnership in support of SPECTA clinical research infrastructure

  • Results of radiotherapy quality assurance in the PEACE-1 trial show high adherence to protocol

  • EORTC presents new precision medicine research results at AACR 2022

  • Joining forces to optimise cancer treatments in clinical practice: EMA & EORTC launch Cancer Medicines Forum with academia

  • MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

  • Promising results for the ultra-low risk patient group in latest MINDACT analysis